Evidence map›Paper›PMID 37883725›Full record

ArticleJCO global oncology2023

Radiotherapy for Brain Metastases Near the End of Life: Characterizing Patients and Tumor Features.

Saulo Brito Silva, Rafael Balsini Barreto, Fernanda Cristina Gonçalves de Oliveira, Gabriela Schmidt Defende Martin, Ofelia Maria Yukie Takiguchi, Iasmin Alves Chirichela, Mário Henrique Furlanetto Miranda, Denize Bodnar, Luiz Augusto Alves Reis, Gabriel Clemente Brito Pereira and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Saulo Brito SilvaDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-2095-4819
Rafael Balsini BarretoCentro de Pesquisas Oncológicas-CEPON, Florianópolis, SP, Brazil.
Fernanda Cristina Gonçalves de OliveiraDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
Gabriela Schmidt Defende MartinDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
Ofelia Maria Yukie TakiguchiDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
Iasmin Alves ChirichelaDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
Mário Henrique Furlanetto MirandaCentro de Pesquisas Oncológicas-CEPON, Florianópolis, SP, Brazil.
Denize BodnarCentro de Pesquisas Oncológicas-CEPON, Florianópolis, SP, Brazil.
Luiz Augusto Alves ReisHospital de Base do Distrito Federal-Universidade de Brasilia, Brasilia, Brazil.
Gabriel Clemente Brito PereiraHospital de Base do Distrito Federal-Universidade de Brasilia, Brasilia, Brazil.ORCID 0000-0002-4984-746X
Isabela Lacerda MirandaHospital Aldenora Bello, São Luis, MA, Brazil.ORCID 0009-0002-4465-8915
Bruno Rodriguez PereiraHospital Aldenora Bello, São Luis, MA, Brazil.
Gustavo Viani ArrudaDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-4337-7575
Fernanda Maris PeriaDepartment of Medical Imaging, Hematology, and Oncology; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0001-5133-165X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with brain metastases are often referred for brain radiotherapy (BrRT) when exclusive palliative management would be more appropriate. To assess the indication of BrRT during end-of-life (EOL) care and evaluate the characteristics of the patients who underwent the treatment.

methodsThis retrospective study comprised patients from four independent oncology centers who had undergone BrRT for metastases. The variables included were Karnofsky performance status (KPS), primary tumor site, metastatic status, neurologic symptomatic status, the number and size of metastases, posterior fossa or meningeal involvement, type of BrRT, having undergone brain metastasectomy, and the availability of systemic therapies after BrRT. Patients were allocated into three subgroups with ≤30, 31-60, and 61-90 days of survival, and a control group of patients who survived >90 days.

resultsA total of 546 patients were included in the study. A KPS of <70 (

conclusionConsidering patients' performance status and whether they are candidates for brain metastasectomy or systemic therapies after BrRT is critical to improving BrRT benefits in scenarios of EOL.

Indexed as

Brain NeoplasmsRadiation OncologyCranial IrradiationDeathHumansRetrospective Studies

Identifiers

PMID37883725
PMCPMC10664862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.